At 10.6% CAGR, the Asia Pacific Lyophilization Services for Biopharmaceuticals Market is projected to be worth US$ 551.97 million by 2028, says Business Market Insights

According to Business Market Insights research, the Asia Pacific lyophilization services for biopharmaceuticals market was valued at US$ 334.18 million in 2023 and is expected to reach US$ 551.97 million by 2028, registering a CAGR of 10.6% from 2023 to 2028. Rising demand for lyophilized products and rapid growth in contract manufacturing and lyophilization services across the region are the critical factors attributed to the Asia Pacific lyophilization services for biopharmaceuticals market expansion.        

There is a lot of scope for applying RNA interference (RNAi) for cancer treatment. RNAi has become a powerful technology for gene function studies and can be used in therapeutic applications. Moreover, after more than 30 years of accumulation, monoclonal antibody drugs have become well-deserved mainstream branches in the field of medicine, from target development to technological improvement. The development of a successful subcutaneous antibody therapy requiring chronic administration at high dosing, particularly when coupled with a prefilled syringe and autoinjector device for at-home administration, depends on the development of a stable formulation at high concentration. To avoid the instability of the aqueous antibody solution, products are stored in a lyophilized (freeze-dried) state. These compounds regularly require freeze-drying to maintain the integrity of the formulation or vehicle to target the small interfering RNA (siRNA) in the body. The long-term stability of therapeutic candidates is necessary for their clinical applications. For most nanoparticle systems formulated in aqueous solutions, lyophilization or freeze-drying is a standard method to ensure long-term stability. Therefore, the rising number of siRNA and antibody-based formulations is expected to become a prevalent trend in the Asia Pacific lyophilization services for biopharmaceuticals market in the coming years.

On the contrary, demerits associated with lyophilization process hampers the Asia Pacific lyophilization services for biopharmaceuticals market.  

Based on service type, the Asia Pacific lyophilization services for biopharmaceuticals market is segmented into lyophilization cycle development, clinical manufacturing, commercial manufacturing, and freeze drying analytical services. The commercial manufacturing segment held 29.34% share of Asia Pacific lyophilization services for biopharmaceuticals market in 2023, amassing US$ 98.03 million. It is projected to garner US$ 152.73 million by 2028 to expand at 9.3% CAGR during 2023–2028. 

Based on end user, the Asia Pacific lyophilization services for biopharmaceuticals market is segmented into pharmaceutical & biotechnology companies, research institutes, and other. The pharmaceutical & biotechnology companies segment held 76.28% share of Asia Pacific lyophilization services for biopharmaceuticals market in 2023, amassing US$ 254.90 million. It is projected to garner US$ 424.80 million by 2028 to expand at 10.8% CAGR during 2023–2028.

Based on country, the Asia Pacific lyophilization services for biopharmaceuticals market  has been categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.59% share of Asia Pacific lyophilization services for biopharmaceuticals market in 2023. It was assessed at US$ 105.56 million in 2023 and is likely to hit US$ 176.85 million by 2028, exhibiting a CAGR of 10.9% during the forecast period.      

Key players dominating the Asia Pacific lyophilization services for biopharmaceuticals market are Curia Global Inc; Emergent BioSolutions Inc; Jubilant HollisterStier LLC.; and PCI Pharma Services, among others. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com